Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by Leerink Partners

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities research analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a report released on Thursday, MarketBeat Ratings reports. The brokerage currently has a $34.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $40.00. Leerink Partners’ price target indicates a potential upside of 52.19% from the stock’s current price.

A number of other brokerages have also recently weighed in on AGIO. HC Wainwright reissued a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday, July 28th. Royal Bank Of Canada lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective for the company. in a report on Wednesday. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $38.67.

Agios Pharmaceuticals Trading Down 50.9%

AGIO stock opened at $22.34 on Thursday. The company’s 50 day moving average is $40.38 and its 200 day moving average is $36.91. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -3.19 and a beta of 0.89. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $62.45.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. The company had revenue of $12.90 million during the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $16.22 EPS. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity

In other news, insider Sarah Gheuens sold 3,302 shares of the stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of the company’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total value of $134,247.27. Following the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at $1,245,399.90. The trade was a 9.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 16,099 shares of company stock valued at $620,092. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AGIO. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the first quarter worth about $40,000. First Horizon Corp purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $45,000. CWM LLC boosted its position in shares of Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 320 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth about $79,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.